Pediatric and Adult Patients with ME/CFS following COVID-19: A Structured Approach to Diagnosis Using the Munich Berlin Symptom Questionnaire (MBSQ)

Laura C. Peo^{1†}, Katharina Wiehler^{1†}, Johannes Paulick¹, Katrin Gerrer¹, Ariane Leone¹, Anja Viereck¹, Matthias Haegele¹, Silvia Stojanov¹, Cordula Warlitz¹, Silvia Augustin¹, Martin Alberer¹, Daniel B. R. Hattesohl², Laura Froehlich³, Carmen Scheibenbogen⁴, Lorenz Mihatsch¹, Rafael Pricoco^{1†}, Uta Behrends^{1,2†*}

¹ MRI Chronic Fatigue Center for Young People (MCFC), Children's Hospital, TUM School of Medicine, Technical University of Munich, Munich, Germany

²German Association for ME/CFS, Hamburg, Germany

³Research Center CATALPA, FernUniversität in Hagen, Hagen, Germany

⁴ Charité Fatigue Center (CFC), Berlin, Germany

[†] These authors contributed equally to this work

*Corresponding author: uta.behrends@mri.tum.de

Short title: Pediatric ME/CFS post-COVID-19 assed by MBSQs

1 ABSTRACT

Purpose: A subset of patients with post-COVID-19 condition (PCC) fulfill the clinical
criteria of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). To establish
the diagnosis of ME/CFS for clinical and research purposes, comprehensive scores have
to be evaluated.

6 **Methods:** We developed the Munich Berlin Symptom Questionnaires (MBSQs) and 7 supplementary scoring sheets (SSSs) to allow for a rapid evaluation of common ME/CFS 8 case definitions. The MBSQs were applied to young patients with chronic fatigue and 9 post-exertional malaise (PEM) who presented to the MRI Chronic Fatigue Center for 10 Young People (MCFC). Trials were retrospectively registered (NCT05778006, 11 NCT05638724).

Results: Using the MBSQs and SSSs, we report on ten patients aged 11 to 25 years diagnosed with ME/CFS after asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19. Results from their MBSQs and from well-established patient-reported outcome measures indicated severe impairments of daily activities and health-related quality of life.

Conclusions: ME/CFS can follow SARS-CoV-2 infection in patients younger than 18
years, rendering structured diagnostic approaches most relevant for pediatric PCC clinics.
The MBSQs and SSSs represent novel diagnostic tools that can facilitate the diagnosis of
ME/CFS in children, adolescents, and adults with PCC and other post-viral syndromes.

Keywords: children, adolescents, ME/CFS, Post-COVID, SARS-CoV-2, post-exertional
 malaise

22 Abbreviations

- 23 ANA, antinuclear antibodies
- 24 CCC, Canadian consensus criteria
- 25 CDC, Centers of Disease Control and Prevention
- 26 CDW-R, clinical diagnostic worksheet of P.C. Rowe et al. (2017)
- 27 CFC, Charité Fatigue Center
- 28 COVID-19, coronavirus disease 2019
- 29 CRP, C-reactive protein
- 30 DSQ, DePaul symptom questionnaire
- 31 EBV, Epstein-Barr virus
- 32 ECG, electrocardiography
- 33 EEG, electroencephalography
- 34 EUROMENE, European Network on ME/CFS
- 35 GET, graded exercise therapy
- 36 HR, heart rate
- 37 HRQoL, health-related quality of life
- 38 IOM, Institute of Medicine
- 39 KBV, German National Association of Statutory Health Insurance Physicians
- 40 MBSQ, Munich Berlin Symptom Questionnaire
- 41 MCFC, MRI Chronic Fatigue Center for Young People
- 42 ME/CFS, myalgic encephalomyelitis / chronic fatigue syndrome
- 43 MRI, TUM university hospital (Klinikum rechts der Isar)
- 44 MRT, magnetic resonance tomography
- 45 NICE, National Institute for Health and Care Excellence
- 46 OH, orthosthatic hypotension
- 47 OI, orthosthatic intolerance
- 48 PASC, post-acute sequelae of COVID-19
- 49 PCC, post-COVID-19 condition

- 50 PCD-J, pediatric case definition by L.A. Jason et al. (2006)
- 51 PEM, post-exertional malaise
- 52 PFT, pulmonary function testing
- 53 PoTS, postural tachcardia syndrome
- 54 PROM, patient-reported outcome measure
- 55 RT-PCR, reverse transcriptase polymerase chain reaction
- 56 SARS-CoV-2, severe acute respiratory coronavirus type 2
- 57 SEID, systemic exertion intolerance disease criteria
- 58 SF-36, Short Form 36
- 59 SSS, Supplementary Scoring Sheet
- 60 UCG, ultrasound cardiography
- 61 WHO, World Health Organisation
- 62
- 63

64 What is known

65 ME/CFS is a frequent debilitating illness. For diagnosis, an extensive differential 66 diagnostic workup is required and the evaluation of clinical ME/CFS criteria. ME/CFS 67 following COVID-19 has been reported in adults but not in pediatric patients younger than 68 19 years of age.

69 What is new

We present novel questionnairs (MBSQs), as tools to assess common ME/CFS case definitions in pediatric and adult patients with post-COVID-19 condition and beyond. We report on ten patients aged 11 to 25 years diagnosed with ME/CFS following asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19.

74 INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic and its long-term-sequelae elicited an unprecedented healthcare crisis worldwide. Beyond acute morbidity and mortality due to infections with severe acute respiratory coronavirus type 2 (SARS-CoV-2) [1; 2], a plethora of post-acute sequelae of COVID-19 (PASC) (often referred to as Long COVID) with or without major organ damage due to SARS-Cov-2 infection are contributing to the post-pandemic burden and are increasingly challenging healthcare systems and societies [3-7].

Most individuals recover from PASC within a few months, but some develop a long-lasting disorder that can severely impair daily function, participation, and health-related quality of life (HRQoL) [4; 8-10]. A post-COVID-19 condition (PCC) (ICD-10 U09.9!) was defined by the World Health Organization (WHO) as continuing or new development of symptoms three months (children: within three months) after the initial SARS-CoV-2 infection, lasting for at least two months and not explained otherwise [11; 12].

PASC were estimated to affect at least 65 million individuals worldwide, with a prevalence of about 10% infected cases and a lower prevalence in children compared to adolescents and adults [4; 13]. Estimating pediatric PCC prevalence is still challenging [8; 14], with 0.8 to 13% reported in controlled cohorts [15; 16] and 2.0 to 3.5% calculated in a metaanalysis covering initially non-hospitalized children and adolescents [17].

93 COVID-19 sequelae may manifest with a wide variety of symptoms, including fatigue, 94 shortness of breath, cognitive dysfunction, pain, sleep disorder, and/or mood symptoms. 95 These symptoms can persist, fluctuate, or relapse and may have a significant impact on 96 everyday functioning [11; 12; 18-20]. Some patients suffer from exertion intolerance with a 97 worsening of symptoms after mild physical and/or mental activities, known as post-98 exertional malaise (PEM) [21; 22]. PEM can last for days or weeks and is recognized as a 99 cardinal symptom of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) [23; 100 24]. ME/CFS following COVID-19 has been reported in adults [21; 25; 26] and in a 19-

year-old male from the U.S. [27; 28] but, to our knowledge, not yet in younger patients.
However, overlapping symptoms of PACS and ME/CFS have been described in pediatric
patients [29].

104 ME/CFS is a complex, chronic neurological disorder (ICD-10 G93.3), triggered mostly by 105 infections and rarely by non-infectious life events [30-32]. Core symptoms include reduced 106 daily functioning with fatigue not alleviated by rest, PEM usually lasting more than a day, 107 unrefreshing sleep, neurocognitive deficits ("brain fog") and/or orthostatic intolerance (OI), 108 with additional symptoms in most cases [33]. Hypothesized pathogenic mechanisms of 109 PCC and ME/CFS overlap, including viral persistence, latent virus reactivation, 110 inflammation, autoimmunity, endothelial dysfunction, and microbiome dysbiosis [23; 34]. 111 Common risk factors of PCC and ME/CFS are female gender, late adolescence or early 112 adulthood, as well as pre-existing chronic health issues [14; 21; 31; 35; 36].

Population-based, pre-pandemic estimates of ME/CFS prevalence ranged from 0.1% to 0.89% in adults [37-40] and from 0.75% to 0.98% in adolescents and children [41; 42], with a high number of undetected cases [42]. Current estimates predicted at least a doubling of ME/CFS cases due to severe PCC [21; 27; 34; 43; 44]. A total of 350.000 and 400.000 ME/CFS cases were documented in 2018 and 2019, and almost 500.000 cases in 2021 by the German National Association of Statutory Health Insurance Physicians (KBV) [45], with no data for children and adolescents available yet.

120 Since up to now, no reliable diagnostic biomarker for ME/CFS was established, complex 121 disorders with compromising chronic fatigue require a thorough differential diagnostic 122 workup and an evaluation of clinical ME/CFS criteria. Most commonly used are the 123 Canadian consensus criteria (CCC) [46] and the broader criteria established by the former 124 Institute of Medicine (IOM) to define "systemic exertion intolerance disease (SEID)" [47]. 125 For children and adolescents, the CCC were adapted by a "pediatric case definition" of 126 L.A. Jason and colleagues (abbreviated here as PCD-J) [48] and in a less restrictive way 127 by the "clinical diagnostic worksheet" designed by P.C. Rowe and colleagues (abbreviated

here as CDW-R) [49]. A symptom duration of at least six months is usually required for adult patients [31]. It was recently suggested to be reduced cross-age to facilitate early treatment by the National Institute of Health and Care Excellence (NICE) [50]. For children and adolescents, the required disease duration is three months in the CCC as well as the IOM and the PCD-J [46-48].

ME/CFS care requires a holistic, longitudinal approach, including extensive patient education, the palliation of symptoms, and adequate psychosocial support. Patients must be carefully guided in "pacing" strategies to avoid PEM ("crashes") [50]. Since gradedexercise strategies (GET) can be harmful to patients with PEM [51] they should not be recommended for patients with ME/CFS [50], although they may be potentially helpful in other forms of PCC [52],

Early identification of patients with ME/CFS is crucial in order to avoid mismanagement and secondary damage, including suicidality. With adequate care, ME/CFS can improve in a substantial number of patients, with recovery documented for the majority of affected children and adolescents within ten years [32]. However, recovery does not imply absence of functional impairment [53]. The lack of ME/CFS-specific knowledge among healthcare professionals [54-56], together with an increasing ME/CFS prevalence, renders more patients at risk of insufficient care and secondary disease.

A challenge in clinical care and research for ME/CFS is the use of various diagnostic
criteria and the lack of specific symptoms. To increase diagnostic sensitivity, the
frequency and severity of symptoms should be assessed [57; 58].

With the Munich Berlin Symptom Questionnaires (MBSQs) we aimed to facilitate the diagnostic approach to adults, adolescents, and children with chronic fatigue following COVID-19 and beyond. The MBSQs represent novel tools for an age-adapted, standardized evaluation of the most common sets of clinical ME/CFS criteria in clinical and research settings.

Here, we present bi-lingual versions of the MBSQs and report on the first ten patients diagnosed with PCC and ME/CFS using the MBSQ in structured medical interviews at our MRI Chronic Fatigue Center For Young People (MCFC). Our Post-COVID clinic was implemented within the MCFC as part of the "Post-COVID Kids Bavaria" project to provide pediatric care and research in the context of severe COVID-19 sequelae [59].

159

160 **PATIENTS AND METHODS**

161 Inclusion Criteria and Clinical Assessment

Ten patients were diagnosed at the MCFC with PCC and ME/CFS using the German 162 163 versions of the novel MBSQs and the supplementary scoring sheets (SSSs) (can be 164 requested from authors, for English translation see Supplementary Materia) (see full 165 description of the MBSQs below). The collection and publication of medical data from 166 these patients was approved by the TUM Ethics Committee (116/21, 511/21). Written 167 informed consent was obtained from all participants (or parents) prior to inclusion. All 168 patients sought care at the MCFC with a history of confirmed (positive reverse 169 transcription polymerase chain reaction (RT-PCR)) or probable (anti-SARS-CoV-2 IgG 170 without prior COVID-19 vaccination and typical COVID-19 symptoms) SARS-CoV-2 171 infection and with post-viral symptoms lasting for more than three months, in accordance 172 with WHO definitions of the PCC at any age.

173 Before visiting the MCFC, the patients had been asked to complete various 174 questionnaires in a stepped routine process, including well-established patient-reported 175 outcome measures (PROMs) to assess fatigue (Fatigue Severity Scale (FSS) [60] or 176 Chalder Fatigue Scale (CFQ) [61]), PEM (DePaul Symptom Questionnaire - Post-177 Exertional Malaise (DSQ-PEM)) [24], limitations in daily functioning (Bell Score) [62], and 178 HRQoL during the last four weeks (Short Form-36 Health Survey (SF-36)) [63]. The 179 MBSQ was developed in 2020 and was provided together with other questionnaires prior 180 to the personal visit to the MCFC.

181 The Bell Score measures daily functioning on a scale from 0% to 100%, with 100% 182 representing normal daily functioning [62]. The DSQ-PEM provides a Likert scale for the 183 frequency (0-4) and severity (0-4) of five different PEM-related symptoms and evaluates 184 the duration of PEM [24]. The SF-36 consists of eight dimensions, including i) physical functioning, ii) social functioning, iii) vitality, iv) general health, v) mental health, vi) role 185 186 physical, vii) role emotional, and viii) bodily pain. The score of each dimension is scaled to 187 0 - 100, with 0 representing the worst and 100 the best health status. The MCFC is 188 focussing on patients with significant fatigue, indicated by a mean score of \geq 5 (maximum: 189 7) in the FSS [64] or of \geq 4 (maximum: 11) in the CFQ bimodal score [65] together with 190 long-lasting PEM (≥14 hours) and reduced daily functioning.

191 Laboratory and technical investigations were performed at the MCFC and/or prior to 192 admission to exclude other disorders that might explain these symptoms. The panel of 193 analyses was selected depending on the individual symptoms, with a core set of routine 194 analyses in line with prior suggestions [49]. Routine blood analyses included a differential 195 cell count as well as C-reactive protein (CRP), liver, kidney, and thyroid function 196 parameters, HbA1c, total serum immunoglobulins, antinuclear antibodies (ANA), 197 antibodies against thyroid peroxidase (TPO), morning cortisol, antibodies against SARS-198 CoV-2 and Epstein-Barr virus (EBV), and EBV DNA load in blood and throat washes 199 (PCR), supplemented by analyses of urine and stool (calprotectin, blood). Routine 200 technical investigations included pulmonary function testing (PFT), electrocardiography 201 (ECG), and ultrasound cardiography (UCG). If indicated, electroencephalography (EEG), 202 cardiac or brain magnetic resonance tomography (MRT), ophthalmological and/or 203 rheumatological assessments were added.

At the MCFC, patients were seen simultaneously by a pediatrician and psychologist or child and adolescent psychiatrist, each trained in ME/CFS, in order to provide a thorough diagnostic assessment. The pediatrician performed a comprehensive interview and physical examination, the psychologist or psychiatrist carried out the psychological

208 evaluation. To assess any OI, including a possible postural orthostatic tachycardia 209 syndrome (PoTS) or orthostatic hypotension (OH), all patients underwent a 10-minute 210 NASA lean test [66]: heart rate (HR) and blood pressure were measured every minute by 211 an electronic device (Carescape V100 Vital Signs Monitor). Patients were asked to hold a 212 supine position for five minutes, then to stand upright and motionless (leaning against the 213 wall with the shoulders and placing the feet two to six inches away from the wall) for ten 214 minutes, and finally to lie down again for five minutes. They were instructed to report any 215 novel symptoms during the whole procedure [49]. The average HR while supine was 216 defined as baseline, and PoTS was defined by a sustained HR \geq 120 beats per minute 217 (bpm) and/or an increase by HR \geq 40 bpm for individuals \leq 19 years and \geq 30 bpm for 218 individuals > 19 years, together with a history of orthostatic symptoms for at least three 219 months [67; 68]. A psychological evaluation was either provided externally or by 220 psychologists trained in ME/CFS at the MCFC.

221 To establish the ME/CFS diagnosis, clinical criteria were evaluated in semi-structured 222 interviews. The MCFC physician went through the pre-filled MBSQ together with the 223 patient (and his/her parents) to avoid any misunderstanding regarding the presence, 224 frequency, and severity of symptoms as well as the duration of PEM. All answers 225 addressing PEM were carefully re-evaluated, and patients were asked to provide 226 examples of typical PEM triggers and "crashes". The pre-filling procedure at home 227 allowed for taking enough time to answer the questionnaire and enabled the physician to 228 focus on aspects to be clarified during the clinical visit. The MBSQ provides additional 229 space for physician's notes next to each question in the MBSQ. After the visit, the 230 physician filled in the SSS for the respective age group in line with answers consented to 231 in the interview and assessed the various case definitions. A final ME/CFS diagnosis was 232 established if at least one case definition was matched and no other explanation of 233 symptoms arose from adequate diagnostic workup. Each case was discussed in an 234 interdisciplinary ME/CFS board, involving several physicians with ME/CFS expertise.

235 **Development of the Munich Berlin Symptom Questionnaire**

The MBSQs and SSSs were designed as a joint collaboration of ME/CFS experts from the MCFC in Munich, the Charité Fatigue Center (CFC) in Berlin, the German Association for ME/CFS in Hamburg, and the Research Center CATALPA in Hagen, Germany. They were developed for clinical and research purposes to facilitate the evaluation of diagnostic ME/CFS criteria in a comprehensive, semi-structured personal or telephone interview by physicians trained in ME/CFS.

242 We chose the IOM criteria and CCC, which require a disease duration of at least six 243 months for adults (≥18 years) as recommended by the Centers for Disease Control and 244 Prevention (CDC) [69] and the European Network for ME/CFS (EUROMENE) [31], 245 respectively. To keep the MBSQs and SSSs for adults as short as possible, we designed 246 a separate version for children and adolescents (< 18 years) that contained not only 247 questions relevant to the CCC and IOM criteria but also additional questions to assess the 248 PCD-J and CDW-R criteria. For practical reasons, the pediatric version of the MBSQs 249 require three months of disease duration for any case definition, although the CDW-R 250 originally suggested to provide only a preliminary diagnosis after three and a confirmed 251 diagnosis after six months [49] (Table 1).

252 We first developed the German versions of the MBSQs and SSSs. All English terms used 253 to describe the symptoms in the original publications [46-49] were attributed to the most 254 adequate of the eight symptom categories of the CCC (fatigue, PEM, sleep disorder, pain, 255 neurocognitive, autonomic, neuroendocrine, and immunologic manifestations). Overlaps 256 and differences were identified, and umbrella terms were introduced if necessary to 257 provide a concise questionnaire. We aimed at the best match of all terms with terms in the 258 original publications and adapted the wording, if necessary, during several rounds of 259 clinical testing and discussion to optimize the understanding by patients and/or parents. 260 To keep the MBSQ as concise as possible, the wording was not adapted for a better 261 understanding for children. The MBSQ was not designed and not evaluated as a patient-

reported outcome measure (PROM) and therefore is not recommended for use as a PROM. The final German versions were translated back to English, aiming at optimal consistency. The English versions was provided to only few English speaking patients at our centers none of which was included in this report.

266 As suggested in the DSQs by Jason and colleagues [57; 58], we used a 5-point Likert 267 scale for quantifying the frequency and severity of symptoms. In line with the DSQs, the 268 MBSQs require an at least moderate frequency and severity (≥ 2) to support the ME/CFS 269 diagnosis. However, instead of two separate columns for "0" answers regarding severity 270 and frequency in the DSQs, the MBSQs provide a single column to indicate that 271 symptoms were not present. In the MBSQs, four additional questions were provided in a 272 dichotomous format to evaluate the presence or absence of distinct features of fatigue or 273 neurocognitive manifestations. Three further questions provided space for three open 274 answers each to gain information on the prominent triggers of PEM, the main symptoms 275 of PEM, and the most bothering symptoms of ME/CFS. In contrast to the very 276 comprehensive DSQ-2 [58], the MBSQ focuses on ME/CFS symptoms only, omitting any 277 further evaluation of medical history.

278 **RESULTS**

279 We developed the MBSQs and SSSs in German (request from authors) and English 280 (Supplementary Material) as novel tools for the clinical assessment of ME/CFS in the 281 context of PCC and beyond. They address the most commonly recommended ME/CFS 282 case definitions (CCC, IOM) and, in the versions for children and adolescents, two 283 additional pediatric case definitions (CDW-R, PCD-J) (Table 1) to facilitate semi-284 structured, age-adapted approaches to diagnosis. Here, we apply the MBSQs and SSSs 285 to patients with PCC and report on the first ten patients diagnosed with ME/CFS according 286 to MBSQ results after a thorough diagnostic workup at our MCFC (Tables 1 and 2, 287 Figures 1 and 2).

The MBSQs were provided to MCFC patients who sought care due to chronic fatigue and PEM. The first ten patients diagnosed with PCC and ME/CFS using the MBSQ included four children and adolescents between 11 and 15 years, and six young adults aged 18 to 25 years, with a male-to-female ratio of 3:7. When presenting at the MCFC, these patients were suffering from PCC symptoms for a period of four to 16 months (**Table 2**).

293 9/10 patients were diagnosed with confirmed or probable COVID-19 and 1/10 with 294 asymptomatic SARS-CoV-2 infection between March 2020 and January 2022. 8/10 295 patients provided a positive SARS-CoV-2 RT-PCR result, and 2/10 patients showed 296 SARS-CoV-2 IgG antibodies without prior COVID-19 vaccination, together with a history 297 of COVID-19-like symptoms. 9/10 patients were initially treated as outpatients, while one 298 adult was hospitalized for four days due to a pre-syncopal episode in the context of 299 COVID-19. An initial loss of smell and/or taste was reported by one adolescent and three 300 adults (Table 2).

Pre-existing medical conditions were present in almost all (9/10) patients, including bronchial asthma (4/10), hypothyroidism (2/10), Grave's disease with hyperthyroidism (1/10), allergies (2/10), attention deficit disorder (1/10), migraine with aura (1/10), history of meningitis (1/10), or Alport's syndrome (1/10) (**Table 2**).

305 The comprehensive diagnostic workup did not reveal any other explanation for the 306 reported complex and debilitating symptoms. Physical and neurological examination, as 307 well as ECG and UCG, showed normal findings in all patients. A cardiac MRI performed 308 on an adult patient revealed a condition after perimyocarditis. In two patients, the PFT 309 showed signs of a hyper-responsive bronchial system, one of which reported pre-existing 310 asthma bronchiale. A cranial MRI was indicated by neurologists in nine and an EEG in 311 eight patients, with normal results except a stable, benign, cystic CNS lesion in one and a 312 transient theta wave slowing in another patient. None of these findings were considered to 313 explain the complex symptoms. 9/10 patients complained of OI, with 5/10 patients 314 meeting the diagnostic criteria for PoTS.

All patients reported significant fatigue in the FSS (9/9) or CFQ (1/1) and screened positive for PEM in the DSQ-PEM, with a PEM duration of more than 24 hours (**Table 2**). Daily functioning measured by the Bell Score ranged between 20% to 60% (median: 30, IQR: 30 - 48.75). All patients considered their symptoms as very debilitating and had significant difficulties with schooling, apprenticeship, or academic studies.

Results from the SF-36 displayed impairment in all dimensions (**Figure 1**) relative to the German norm sample for the age of 14 to 20 years [70]. The physical component summary (PCS) was markedly reduced in our group of ME/CFS patients compared to the German norm population, with a mean score of 24.9 compared to 53.4 (P < 0.001). The mean mental component summary score was 44.9 versus 45.0, respectively (P = 0.982) [70].

All patients experienced substantial reductions in occupational, educational, and/or personal activities, indicated by scoring at or below at least two of the three following subscale cut-offs on the SF-36: role physical \leq 50, social functioning \leq 62.5, and vitality \leq 329 35, as required by the original CCC and the PCD-J [71]. Compared to patients suffering 330 from mild to moderate depression (n = 60, mean age 17.5 ±1.6 years) [72], our ME/CFS 331 patients had significantly reduced scores in the subscales physical functioning (P <

332 0.001), role physical (P < 0.001), bodily pain (P < 0.001), vitality (P = 0.002), and social 333 functioning (P = 0.016). Only in the two subscales role emotional (P < 0.001) and mental 334 health (P < 0.001) our patients scored significantly higher than the control group of 335 adolescents and young adults with moderate to severe depression. The subscale general 336 health was not significantly different (P = 0.082) (**Figure 1**).

All patients fulfilled at least one ME/CFS case definition addressed in the MBSQ. One child fulfilled the CCC and the PDW-R but not the IOM and the PCD-J. Two adolescents met all four sets of criteria, while one met only the broader PDW-R and IOM criteria. All adults fulfilled the CCC, but one did not match the IOM criteria since sleep was not recognized as "unrefreshing" (**Table 2**).

The most common ME/CFS symptoms were fatigue (10/10), limitations in daily life (10/10), long-lasting PEM (10/10), unrefreshing sleep (9/10), neurocognitive manifestations (10/10) (e.g., concentration and memory problems), and dizziness (6/10). The most bothering symptoms, the total amount of symptoms, as well as the frequency and severity of symptoms varied individually (**Table 2**, **Figure 2**).

347

348 **DISCUSSION**

The MBSQs and SSSs are novel, age-adapted, concise diagnostic tools developed to facilitate the evaluation of ME/CFS criteria in patients with fatigue following COVID-19 and beyond. We reported ten young PCC patients who were diagnosed with ME/CFS using the MBSQ. To our knowledge, this is the first report on ME/CFS in people with PCC younger than 18 years.

Very little is known about the prevalence of severe PCC in children and adolescents. A survey over a four-week period ending 30 March 2023 on the prevalence of ongoing symptoms following SARS-CoV-2 infection in U.K. households indicated that sequelae defined as "limiting day-to-day activities" manifested less often in children aged 2-11 years

358 (0.1%) compared to adolescents and young adults (12-24 years) (0.26 - 0.33%) and 359 adults aged \geq 25 years (0.46 - 0.92%) [73]. However, early in the pandemic, a report from 360 Sweden indicated that pediatric PCC can compromise school education for several 361 months [74], and a single 19-year-old adolescent with post-COVID-ME/CFS was 362 documented in the US [27; 28]. Meanwhile, additional pediatric patients were diagnosed 363 with ME/CFS at our MCFC and at several partner sites of our recently implemented 364 multicenter long COVID (NCT05638724) and ME/CFS registries (NCT05778006), as will 365 be reported in more detail (unpublished results).

366 ME/CFS, in general, is well documented in children and adolescents [49]. In a pre-367 pandemic pediatric cohort from Australia, ME/CFS was reported to have followed 368 infections in up to 80% of cases, with EBV infection accounting for 40% of cases [32]. 369 12.9%, 7.3%, and 4.3% of adolescents in a pre-pandemic U.S. cohort presented with 370 ME/CFS as defined by the PCD-J criteria at six, 12, and 24 months after EBV-induced 371 infectious mononucleosis [75]. ME/CFS defined by meeting at least one of three case 372 definitions (Fukuda, IOM, CCC) manifested in 23% of U.S. college students following 373 symptomatic primary EBV infection, with 8% of the cohort fulfilling the CCC [76]. The 374 prognosis of ME/CFS was reported to be more favorable in children and adolescents 375 compared to adults, with recovery rates of 38% after five years and 68% after ten years 376 and a mean illness duration of five (range 1-15) years in those who recovered [32]. Post-377 viral ME/CFS and partial recovery thereof was also documented at the MCFC [77]. Taken 378 together, pediatric ME/CFS following infection with SARS-CoV-2 was not unexpected and 379 might be transient, at least in some cases, if diagnosed and treated in a correct and timely 380 way.

Reports of ME/CFS after SARS-CoV-2 infection in adults have been published, including
reports from Germany [21; 25; 27]. However, little is known about the pediatric population.
To our knowledge, this is the first report on ME/CFS in PCC patients aged less than 18
years, including children as young as 11 years. All reported patients had developed long-

lasting typical symptoms after asymptomatic SARS-CoV-2 infection or mild to moderate courses of documented or probable COVID-19 with no other medical explanation and impairment of daily life, according to the WHO definition of PCC [11]. A substantial reduction in occupational, educational, and/or personal activities of these patients was confirmed by a Bell score of ≤ 60% and by scoring at or below at least two of three subscale cut-offs on the SF-36 (role physical ≤ 50, social functioning ≤ 62.5, and vitality ≤ 35) [71].

392 In line with current evidence indicating a lower prevalence of severe PCC in children 393 younger than 12 years compared to adolescents and adults [73], 9 of 10 of our patients 394 were older than 12 years. At the MCFC, we are regularly seeing young adults up to the 395 age of 20 years since their healthcare needs, in general, do not substantially differ from 396 those of older adolescents and include features such as school or peer group integration 397 that might not be fully covered by healthcare institutions for adult patients. Moreover, 398 patients turning 18 years had been excluded from other pediatric PCC follow-up studies 399 indicating a possible lack of data in this age group [78].

The general lack of data regarding ME/CFS following SARS-CoV-2 and other infections may, in part, be explained by insufficient disease-specific knowledge and experience [49; 54]. Further, the comparison of published data is challenging due to the different ME/CFS case definitions used worldwide [79; 80]. Thus, harmonization of diagnostic criteria for ME/CFS is urgently needed. High time and cost expenses for the diagnostic workup, moreover, may prevent clinicians from diagnosing ME/CFS and as a result these patients often get no adequate care.

The MBSQs and SSSs were developed as concise tools that can facilitate and harmonize diagnostic workup in clinical and research centers currently faced with PCC and other post-infection syndromes. They provide a standardized basis for a semi-structured medical interview. The interview guarantees to rule out any misunderstanding, especially

411 concerning PEM, the key feature of ME/CFS. Thus, the MBSQs may be pre-filled by412 patients at home but should not be used as PROMs.

413 Our approach was based on the DSQs developed as PROMs by L.A. Jason and 414 colleagues to evaluate ME/CFS diagnosis and associated features in studies with adults, 415 adolescents, and children [57]. Like the DSQs, the MBSQs offer Likert scales for the 416 quantification of symptoms, with a threshold of \geq 2 for both frequency and severity to 417 indicate diagnostic relevance. Moreover, as introduced by the DSQs, the SSSs provide an 418 algorithm to evaluate different case definitions using a single questionnaire.

In contrast to the DSQs, the MBSQs neither address demographics nor do they evaluate the medical, occupational, and social history since many PCC centers might want to follow their own respective questionnaires and since some items of the DSQs are related to specific settings in the US. Furthermore, in contrast to the DSQ-2, the MBSQs do not address the comprehensive international consensus criteria (ME-ICC) because they were not recommended by the European Network for ME/CFS (EUROMENE) [31].

425 Importantly, the MBSQs are setting a cut-off at ≥14 hours regarding the PEM duration for 426 the CCC as well as for the PCD-J and CDW-R criteria while leaving the IOM criteria 427 without. Previous ME/CFS studies indicated that PEM lasts longer than 24 hours in most 428 patients [24]. Some ME/CFS case definitions required a duration of at least 24 hours, 429 including the CDW-R ("Recovery takes more than 24h") [49]. The original publications of 430 the CCC and the PCD-J stated that "there is a pathologically slow recovery period-usually 431 24 hours or longer" (CCC) [46] and that "the recovery is slow, often taking 24 hours or 432 longer" (PCD-J) [48]), respectively. For the MBSQs, we chose a PEM duration cut-off at \geq 433 14 hours since it included more ME/CFS patients than a cut-off at \geq 24 hours but still 434 excluded the majority of patients with other chronic diseases in a previous study [24]. 435 However, since the MBSQs offer various durations of PEM, they allow for the investigation 436 of subgroups for research purposes.

The broader IOM criteria included in the MBSQ were recommended for clinical diagnosis by the EUROMENE and by the CDC in the US. The IOM criteria lack, however, a definition of the length of PEM and do not require cognitive symptoms. In PCS, the assessment of the length of PEM is, however, important as it defines subgroups of patients with different biomarker profiles and clinical courses [21; 81-84]. Uniform use of one case definition in clinical practice would allow for reasonable comparability of healthcare data on ME/CFS worldwide, including ME/CFS in the context of PCC.

444 The MBSQs have several limitations. First, results have not been compared with results 445 from other questionnaires investigating ME/CFS case definitions such as e.g. the DSQ-2 446 for reasons of practicability. Patients at the MCFC have to fill in a long list of 447 questionnaires which is challenging many of them to an extent that prevents adding 448 additional questionnaires. However, we are recommending the MBSQs not as a PROM 449 but as a tool to facilitate a structured medical interview which can be recognized as the 450 gold standard for evaluating diagnostic ME/CFS criteria. A comparison of results from pre-451 filled MBSQs, with MBSQ results from the medical visits as well as with results from other 452 questionnaires, will be an important future goal. Second, the low number and 453 heterogeneity of cases regarding age, gender, and pre-existing morbidity did not allow for 454 correlation and consistency analyses of MBSQ results. This will be aimed at using results 455 from a larger group of future patients. Third and most importantly, a structured medical 456 interview based on well-designed questionnaires cannot substitute for a future diagnostic 457 biomarker for ME/CFS and/or PEM. Without a diagnostic biomarker, diagnosing the 458 complex symptom PEM and PEM duration will remain challenging, especially in patients 459 who are largely preventing long-lasting "crashes" by successful pacing. Last but not least, 460 here we only report on patients who eventually met any ME/CFS case definition. In 461 ongoing studies, we are evaluating the MBSQ in the context of healthy individuals and 462 patients with other chronic diseases.

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

463	Taken together, the MBSQs and SSSs were developed to standardize and accelerate
464	ME/CFS diagnosis at any age in clinical practice and research and were successfully
465	applied to children, adolescents, and young adults with PCC. Standardization in PCC and
466	ME/CFS research is urgently needed to compare clinical studies, identify biomarkers, and
467	eventually select and develop specific treatment approaches [85].

469 **Conclusion**

470 We have developed and successfully applied a set of novel diagnostic questionnaire and 471 scoring sheets to identify children, adolescents, and adults with ME/CFS following SARS-472 CoV-2 infection and beyond. These questionnaires can aid clinicians in assessing up to 473 four case definitions of ME/CFS in a quantitative and standardized manner. The 474 questionnaires include the broader IOM criteria recommended by experts in the U.S. and 475 Europe for clinical care as well as the stricter CCC and, for children and adolescents, two 476 additional pediatric case definitions. These novel tools allow for assessing the frequency 477 and severity of ME/CFS symptoms as well as the duration of PEM and thereby support 478 further research on these features in the context of ME/CFS diagnosis. In sum, we expect 479 the MBSQs to facilitate patient care and research in the context of ME/CFS in pediatrics 480 and beyond.

481

482 Acknowledgments

We thank all patients who participated in the project as well as their families, forsupporting the participation.

485 **REFERENCES**

- 486 1. Pei S, Yamana TK, Kandula S, Galanti M, Shaman J (2021) Burden and characteristics of
 487 COVID-19 in the United States during 2020. Nature 598:338-341
- 488 2. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J (2023) The
 489 WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature
 490 613:130-137
- 491 3. Mueller MR, Ganesh R, Hurt RT, Beckman TJ (2023) Post-COVID Conditions. Mayo Clin Proc
 492 98:1071-1078
- 493 4. Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms
 494 and recommendations. Nat Rev Microbiol 21:133-146
- 495 5. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, et al.
 496 (2021) Post-acute COVID-19 syndrome. Nat Med 27:601-615
- 497 6. Carfi A, Bernabei R, Landi F (2020) Persistent Symptoms in Patients After Acute COVID-19.
 498 Jama 324:603-605
- 499 7. Han Q, Zheng B, Daines L, Sheikh A (2022) Long-Term Sequelae of COVID-19: A Systematic
- 500 Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms.
 501 Pathogens 11
- 8. Zimmermann P, Pittet LF, Curtis N (2022) The Challenge of Studying Long COVID: An Updated
 Review. Pediatr Infect Dis J 41:424-426
- 504 9. Zimmermann P, Pittet LF, Curtis N (2021) How Common is Long COVID in Children and
 505 Adolescents? Pediatr Infect Dis J 40:e482-e487
- 506 10. Office for National Statistics (2023) Prevalence of ongoing symptoms following coronavirus
 507 (COVID-19) infection in the UK: 2 February 2023.
- 508 11. World Health Organization (2023) A clinical case definition for post COVID-19 condition in
 509 children and adolescents by expert consensus. World Health Organization

- 510 12. World Health Organization (2021) A clinical case definition of post COVID-19 condition by a
- 511 Delphi consensus. World Health Organization, Geneva, Switzerland
- 512 13. Scharf RE, Anaya JM (2023) Post-COVID Syndrome in Adults-An Overview. Viruses 15
- 513 14. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL (2022) Prevalence and clinical
 514 presentation of long COVID in children: a systematic review. Eur J Pediatr 181:3995-4009
- 515 15. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, Murray B, Kläser K,
- 516 Kerfoot E, Chen L, Deng J, Hu C, Selvachandran S, Read K, Capdevila Pujol J, Hammers
- 517 A, Spector TD, Ourselin S, Steves CJ, Modat M, Absoud M, Duncan EL (2021) Illness

518 duration and symptom profile in symptomatic UK school-aged children tested for SARS-

- 519 CoV-2. Lancet Child Adolesc Health 5:708-718
- 520 16. Stephenson T, Pinto Pereira SM, Shafran R, de Stavola BL, Rojas N, McOwat K, Simmons R,
 521 Zavala M, O'Mahoney L, Chalder T, Crawley E, Ford TJ, Harnden A, Heyman I, Swann O,
 522 Whittaker E, Consortium C, Ladhani SN (2022) Physical and mental health 3 months after
 523 SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national
 524 matched cohort study. Lancet Child Adolesc Health 6:230-239
- 525 17. Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, Puhan MA (2022) Long
 526 COVID Through a Public Health Lens: An Umbrella Review. Public Health Rev 43:1604501
- 18. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado
 J, Singh R, Collins T, O'Connor RJ, Sivan M (2021) Postdischarge symptoms and
 rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med
 Virol 93:1013-1022
- 19. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O'Connor L, Leavy D, O'Brien
 K, Dowds J, Sugrue JA, Hopkins D, Martin-Loeches I, Ni Cheallaigh C, Nadarajan P,
 McLaughlin AM, Bourke NM, Bergin C, O'Farrelly C, Bannan C, Conlon N (2020)
 Persistent fatigue following SARS-CoV-2 infection is common and independent of severity
 of initial infection. PLoS One 15:e0240784
 - 23

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 20. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, Rodrigues NB, Subramaniapillai M, Di
 Vincenzo JD, Cao B, Lin K, Mansur RB, Ho RC, Rosenblat JD, Miskowiak KW, Vinberg M,
 Maletic V, McIntyre RS (2022) Fatigue and cognitive impairment in Post-COVID-19
 Syndrome: A systematic review and meta-analysis. Brain Behav Immun 101:93-135
- 540 21. Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Hanitsch LG, Zoller T, Steinbeis F, Haffke M,
 541 Rudolf G, Heidecker B, Bobbert T, Spranger J, Volk H-D, Skurk C, Konietschke F, Paul F,
 542 Behrends U, Bellmann-Strobl J, Scheibenbogen C (2022) A prospective observational
 543 study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in
 544 Germany and biomarkers associated with symptom severity. Nature Communications
 545 13:5104
- 546 22. Jason LA, Dorri JA (2022) ME/CFS and Post-Exertional Malaise among Patients with Long
 547 COVID. Neurol Int 15:1-11
- 548 23. Choutka J, Jansari V, Hornig M, Iwasaki A (2022) Unexplained post-acute infection syndromes.
 549 Nature Medicine 28:911-923
- 550 24. Cotler J, Holtzman C, Dudun C, Jason LA (2018) A Brief Questionnaire to Assess Post551 Exertional Malaise. Diagnostics (Basel) 8
- 25. Bonilla H, Quach TC, Tiwari A, Bonilla AE, Miglis M, Yang PC, Eggert LE, Sharifi H,
 Horomanski A, Subramanian A, Smirnoff L, Simpson N, Halawi H, Sum-ping O, Kalinowski
 A, Patel ZM, Shafer RW, Geng LN (2023) Myalgic Encephalomyelitis/Chronic Fatigue
 Syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results
 from a post-COVID-19 multidisciplinary clinic. Front Neurol 14:1090747
- 557 26. González-Hermosillo JA, Martínez-López JP, Carrillo-Lampón SA, Ruiz-Ojeda D, Herrera 558 Ramírez S, Amezcua-Guerra LM, Martínez-Alvarado MDR (2021) Post-Acute COVID-19
 559 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A
- 560 6-Month Survey in a Mexican Cohort. Brain Sci 11

- 561 27. Petracek LS, Suskauer SJ, Vickers RF, Patel NR, Violand RL, Swope RL, Rowe PC (2021)
 562 Adolescent and Young Adult ME/CFS After Confirmed or Probable COVID-19. Front Med
 563 (Lausanne) 8:668944
- 28. Petracek LS, Broussard CA, Swope RL, Rowe PC (2023) A Case Study of Successful
 Application of the Principles of ME/CFS Care to an Individual with Long COVID. Healthcare
 (Basel) 11
- 567 29. Jason LA, Johnson M, Torres C (2023) Pediatric Post-Acute Sequelae of SARS-CoV-2
 568 infection. Fatigue: Biomedicine, Health & Behavior:1-11
- 30. Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, Scheibenbogen C,
 Murovska M, Prusty BK (2018) Chronic viral infections in myalgic
 encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med 16:268
- 31. Nacul L, Authier FJ, Scheibenbogen C, Lorusso L, Helland IB, Martin JA, Sirbu CA, et al.
 (2021) European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
 (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of
 People with ME/CFS in Europe. Medicina (Kaunas) 57
- 576 32. Rowe KS (2019) Long Term Follow up of Young People With Chronic Fatigue Syndrome
 577 Attending a Pediatric Outpatient Service. Front Pediatr 7:21
- 578 33. Estévez-López F, Mudie K, Wang-Steverding X, Bakken IJ, Ivanovs A, Castro-Marrero J, Nacul 579 L, Alegre J, Zalewski P, Słomko J, Strand EB, Pheby D, Shikova E, Lorusso L, Capelli E, 580 Sekulic S, Scheibenbogen C, Sepúlveda N, Murovska M, Lacerda E (2020) Systematic 581 Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue 582 Svndrome Across Europe: Current Evidence and EUROMENE Research 583 Recommendations for Epidemiology, J Clin Med 9
- 584 34. Komaroff AL, Lipkin WI (2021) Insights from myalgic encephalomyelitis/chronic fatigue
 585 syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends
 586 Mol Med 27:895-906

- 35. Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, Ladhani
 SN, De Stavola BL, Viner RM, Swann OV (2022) Persistent symptoms following SARSCoV-2 infection amongst children and young people: A meta-analysis of controlled and
 uncontrolled studies. J Infect 84:158-170
- 36. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, Clark A,
 Ntatsaki E, Vassiliou VS (2023) Risk Factors Associated With Post-COVID-19 Condition: A
 Systematic Review and Meta-analysis. JAMA Intern Med 183:566-580
- 37. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, Leite JC, Poland F, Howe
 A, Drachler ML (2011) Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome
 (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care.
 BMC Med 9:91
- 38. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W,
 Huang CF, Plioplys S (1999) A community-based study of chronic fatigue syndrome. Arch
 Intern Med 159:2129-2137
- 39. Jason L, Mirin A (2021) Updating the National Academy of Medicine ME/CFS prevalence and
 economic impact figures to account for population growth and inflation. Fatigue:
 Biomedicine, Health & Behavior 9:9-13
- 40. Lim E-J, Ahn Y-C, Jang E-S, Lee S-W, Lee S-H, Son C-G (2020) Systematic review and metaanalysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis
 (CFS/ME). Journal of translational medicine 18:1-15
- 41. Crawley EM, Emond AM, Sterne JAC (2011) Unidentified Chronic Fatigue Syndrome/myalgic
 encephalomyelitis (CFS/ME) is a major cause of school absence: surveillance outcomes
 from school-based clinics. BMJ Open 1:e000252
- 42. Jason LA, Katz BZ, Sunnquist M, Torres C, Cotler J, Bhatia S (2020) The Prevalence of
 Pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in a Community[®]Based
 Sample. Child Youth Care Forum 49:563-579

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 43. Mirin AA, Dimmock ME, Jason LA (2022) Updated ME/CFS prevalence estimates reflecting
 post-COVID increases and associated economic costs and funding implications. Fatigue:
 Biomedicine, Health & Behavior 10:83-93
- 44. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, Wende D, et al. (2022) PostCOVID-19-associated morbidity in children, adolescents, and adults: A matched cohort
 study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med
 19:e1004122
- 45. Kassenärztliche Bundesvereinigung (2023) Öffentliche Anhörung im Ausschuss für Gesundheit
 des deutschen Bundestages am 19. April 2023. Stellungnahme der KBV zum Antrag der
 CDU/CSU-Bundestagsfraktion "ME/CFS-Betroffenen sowie deren Angehörigen helfen –
 Für eine bessere Gesundheits- sowie Therapieversorgung, Aufklärung und Anerkennung.
- 46. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, FlorHenry P, Joshi P, Powles ACP, Sherkey JA, van de Sande MI (2003) Myalgic
 Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Chronic Fatigue Syndrome 11:7115
- 47. Clayton EW (2015) Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report
 on redefining an illness. Jama 313:1101-1102
- 48. Jason LA, Jordan K, Miike T, Bell DS, Lapp C, Torres-Harding S, Rowe K, Gurwitt A, De
 Meirleir K, Van Hoof ELS (2006) A Pediatric Case Definition for Myalgic Encephalomyelitis
 and Chronic Fatigue Syndrome. Journal of Chronic Fatigue Syndrome 13:1-44
- 49. Rowe PC, Underhill RA, Friedman KJ, Gurwitt A, Medow MS, Schwartz MS, Speight N, Stewart
 JM, Vallings R, Rowe KS (2017) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
 Diagnosis and Management in Young People: A Primer. Front Pediatr 5:121
- 50. National Institute for Health and Care Excellence (2021) Myalgic encephalomyelitis (or
 encephalopathy)/chronic fatigue syndrome: diagnosis and management.

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 51. Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, Dempsey TT, Dimmock ME,
- 639 Dowell TG, Felsenstein D, Kaufman DL, Klimas NG, Komaroff AL, Lapp CW, Levine SM,
- 640 Montoya JG, Natelson BH, Peterson DL, Podell RN, Rey IR, Ruhoy IS, Vera-Nunez MA,
- 641 Yellman BP (2021) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of
- 642 Diagnosis and Management. Mayo Clinic Proceedings 96:2861-2878
- 52. National Institute for Health and Care Excellence: Clinical Guidelines (2021) COVID-19 rapid
 guideline: managing the long-term effects of COVID-19. National Institute for Health and
 Care Excellence (UK), London, England
- 53. Brown MM, Bell DS, Jason LA, Christos C, Bell DE (2012) Understanding long-term outcomes
 of chronic fatigue syndrome. Journal of clinical psychology 68:1028-1035
- 54. Hng KN, Geraghty K, Pheby DFH (2021) An Audit of UK Hospital Doctors' Knowledge and
 Experience of Myalgic Encephalomyelitis. Medicina (Kaunas) 57
- 55. Froehlich L, Hattesohl DBR, Jason LA, Scheibenbogen C, Behrends U, Thoma M (2021)
 Medical Care Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue
 Syndrome in Germany. Medicina (Kaunas) 57
- 56. Froehlich L, Niedrich J, Hattesohl DBR, Behrends U, Kedor C, Haas JP, Stingl M,
 Scheibenbogen C (2023) Evaluation of a webinar to increase health professionals'
 knowledge about Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS).
 Manuscript submitted for publication
- 57. Jason LA, Sunnquist M (2018) The Development of the DePaul Symptom Questionnaire:
 Original, Expanded, Brief, and Pediatric Versions. Front Pediatr 6:330
- 58. Bedree H, Sunnquist M, Jason LA (2019) The DePaul Symptom Questionnaire-2: A Validation
 Study. Fatigue 7:166-179
- 59. Bavarian State Ministry of Health and Care (2021) Modellprojekt "Post-COVID Kids Bavaria".
- 662 Teilprojekt 2 "Post-COVID Kids Bavaria PCFC" (Post-COVID Fatigue Center). Bavarian
 663 State Ministry of Health and Care

- 664 60. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The Fatigue Severity Scale:
 665 Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus.
 666 Archives of Neurology 46:1121-1123
- 667 61. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP (1993)
 668 Development of a fatigue scale. J Psychosom Res 37:147-153
- 669 62. Bell DS (1994) The doctor's guide to chronic fatigue syndrome: understanding, treating, and
 670 living with CFIDS. Da Capo Press
- 671 63. Ware JE, Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I.

672 Conceptual framework and item selection. Med Care 30:473-483

673 64. Lerdal A, Wahl A, Rustoen T, Hanestad BR, Moum T (2005) Fatigue in the general population:

a translation and test of the psychometric properties of the Norwegian version of thefatigue severity scale. Scand J Public Health 33:123-130

- 676 65. Jackson C (2015) The Chalder Fatigue Scale (CFQ 11). Occup Med (Lond) 65:86
- 677 66. Lee J, Vernon SD, Jeys P, Ali W, Campos A, Unutmaz D, Yellman B, Bateman L (2020)
- 678 Hemodynamics during the 10-minute NASA Lean Test: evidence of circulatory 679 decompensation in a subset of ME/CFS patients. J Transl Med 18:314
- 680 67. World Health Organization (2018) ICD-11 MMS. International Classification of Diseases for
 681 Mortality and Morbidity Statistics. 8D89.2 Postural orthostatic tachycardia syndrome
- 682 68. Vernino S, Bourne KM, Stiles LE, Grubb BP, Fedorowski A, Stewart JM, Arnold AC, et al.
 683 (2021) Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical
 684 care from a 2019 National Institutes of Health Expert Consensus Meeting Part 1. Auton
 685 Neurosci 235:102828
- 686 69. Centers for Disease Control and Prevetion (2021) Symptoms and Diagnosis of ME/CFS. CDC

Pediatric ME/CFS post-COVID-19 assed by MBSQs_2023 07 22

- 70. Bellach B-M, Ellert U, Radoschewski M (2000) Der SF-36 im Bundes-Gesundheitssurvey Erste
 Ergebnisse und neue Fragen: Erste Ergebnisse und neue Fragen.
 Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 43:210-216
- 690 71. Jason L, Brown M, Evans M, Anderson V, Lerch A, Brown A, Hunnell J, Porter N (2011)

691 Measuring substantial reductions in functioning in patients with chronic fatigue syndrome.692 Disabil Rehabil 33:589-598

- Kristjánsdóttir J, Olsson GI, Sundelin C, Naessen T (2011) Could SF-36 be used as a
 screening instrument for depression in a Swedish youth population? Scandinavian journal
 of caring sciences 25:262-268
- 696 73. Office for National Statistics (2023) Prevalence of ongoing symptoms following coronavirus
 697 (COVID-19) infection in the UK: 30 March 2023.
- 698 74. Ludvigsson JF (2021) Case report and systematic review suggest that children may experience
 699 similar long-term effects to adults after clinical COVID-19. Acta Paediatr 110:914-921
- 700 75. Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R (2009) Chronic fatigue syndrome after
 701 infectious mononucleosis in adolescents. Pediatrics 124:189-193
- 702 76. Jason LA, Cotler J, Islam MF, Sunnquist M, Katz BZ (2021) Risks for Developing Myalgic
 703 Encephalomyelitis/Chronic Fatigue Syndrome in College Students Following Infectious
 704 Mononucleosis: A Prospective Cohort Study. Clin Infect Dis 73:e3740-e3746
- 705 77. Pricoco R, Meidel P, Hofberger T, Zietemann H, Mueller Y, Wiehler K, Michel K, Paulick J, 706 Leone A, Haegele M, Mayer-Huber S, Gerrer K, Mittelstrass K, Scheibenbogen C, Renz-707 Polster H, Mihatsch L, Behrends U (2023) One-Year Follow-up of Young People with 708 ME/CFS Following Infectious Mononucleosis by Epstein-Barr Virus. 709 medRxiv:2023.2007.2024.23293082
- 710 78. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S (2022) Long COVID
 711 symptoms and duration in SARS-CoV-2 positive children a nationwide cohort study. Eur J
 712 Pediatr 181:1597-1607

- 713 79. VanElzakker MB, Brumfield SA, Lara Mejia PS (2018) Neuroinflammation and Cytokines in
 714 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of
 715 Research Methods. Front Neurol 9:1033
- 80. Conroy KE, Islam MF, Jason LA (2022) Evaluating case diagnostic criteria for myalgic
 encephalomyelitis/chronic fatigue syndrome (ME/CFS): toward an empirical case definition.
 Disability and Rehabilitation:1-8
- 81. Legler AF, Meyer-Arndt L, Mödl L, Kedor C, Freitag H, Stein E, Hoppmann U, Rust R,
 Konietschke F, Thiel A, Paul F, Scheibenbogen C, Bellmann-Strobl J (2023) Symptom
 persistence and biomarkers in post-COVID-19/chronic fatigue syndrome results from a
 prospective observational cohort. medRxiv:2023.2004.2015.23288582
- 82. Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, Sepulveda N, et al. (2022)
 Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post
 COVID Syndrome correlate with symptom severity. Front Immunol 13:981532
- 83. Haffke M, Freitag H, Rudolf G, Seifert M, Doehner W, Scherbakov N, Hanitsch L, Wittke K,
 Bauer S, Konietschke F, Paul F, Bellmann-Strobl J, Kedor C, Scheibenbogen C, Sotzny F
 (2022) Endothelial dysfunction and altered endothelial biomarkers in patients with post-
- 729 COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med 20:138
- 730 84. Flaskamp L, Roubal C, Uddin S, Sotzny F, Kedor C, Bauer S, Scheibenbogen C, Seifert M
 731 (2022) Serum of Post-COVID-19 Syndrome Patients with or without ME/CFS Differentially
 732 Affects Endothelial Cell Function In Vitro. Cells 11
- 85. Wong TL, Weitzer DJ (2021) Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue
 Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and
 Symptomatology. Medicina (Kaunas) 57

736

737 STATEMENTS AND DECLARATIONS

738 Funding

This work was supported by the StMGP as well as the Weidenhammer-Zoebele and theLost-Voices foundations.

741

742 Competing Interests

U.B. received research grants from the Federal Ministry of Education and Research (BMBF), the Federal Ministry of Health (BMG), the Bavarian Ministry of Health and Care (StMGP), the Bavarian Ministry of Science and Arts (StMWK), the German Center for Infection Research (DZIF), the People for Children (Menschen für Kinder) foundation, the Weidenhammer-Zöbele foundation, the Lost-Voices foundation, and the ME/CFS research foundation.

C.S. was consulting Roche, Celltrend, and Bayer; she received support for clinical trials by
Bayer, Fresenius, and Miltenyi, honoraria for lectures by Fresenius, AstraZeneca, BMS,
Roche, Bayer, and Novartis, and research grants from the German Research Association
(DFG), the BMBF, the BMG, the Weidenhammer-Zöbele foundation, the Lost-Voices
foundation, and the ME/CFS research foundation.

- The other authors declare no conflict of interest.
- 755

756 Author contribution statement

Conceptualization: L.C.P, K.W., R.P., K.G., J.P., A.L., U.B.. Methodology: L.C.P, K.W.,
R.P., K.G., J.P., A.L., C.S., D.H., L.F., U.B.. Data curation, L.C.P., R.P., A.V.. Formal
analysis: L.C.P., R.P., L.M. Draft writing: L.C.P, K.W., R.P.. Editing: L.C.P, R.P., M.H.,
M.A., A.V., A.L., S.S., S.A., C.W., D.H., L.F., L.M., C.S., U.B.. Figures: R.P., L.M..

761 Supervision, U.B.. Acquisition of Funding: U.B.. All authors contributed to the final762 manuscript. All authors have read and agreed to the published version of the manuscript.

763

764 Ethical Approval

The study was conducted according to the guidelines of the Declaration of Helsinki and
approved by the Ethics Committee of the University Hospital of the Technical University of
Munich (116/21, 511/21).

768

769 Consent to Participate

Written informed consent was obtained from all subjects (or their legal guardian) involvedin the study.

772

773 Data Availability Statement

The data that support the findings of this study are available from the correspondingauthor, U.B., upon reasonable request.

776 TABLES

Table 1. MBSQ versions for different age groups								
Version	Adressed period of symptoms		Age group CCC		PCD-J	CDW-R		
Children and Adolescents	Past 3 months	0-17 years	+	+	+	+		
Adults	Past 6 months	≥ 18 years	+	+	-	-		

MBSQ, Munich Berlin Symptom Questionnaire; CCC, Canadian Consensus Criteria, 2003 [46]; IOM, Criteria of the former Institute of Medicine, 2015 [47]; PCD-J, Pediatric Case Definition by Jason et al., 2006 [48] ; CDW-R, Clinical Diagnostic Worksheet by Rowe et al., 2017 [49];

Pediatric ME/CES post-COVID-19 assed by MBSQs_2023 07 22

Table 2. Clinical Data of Patients with MECFS following SARS-CoV-2 infection											
	Patient	1	2	3	4	5	6	7	8	9	10
	Sex	М	М	F	М	F	F	F	F	F	F
	Age range (years)	11-15				18-25					
COVID- 19	Loss of smell/ taste	-	-	+	-	-	+	+	-	-	+
	RT-PCR	+	+	n. d.	+	+	+	+	n. d.	+	+
	Antibodies ¹	+	+	+	n. d.	+	+	n. d.	+	n.d.	+
	Medical care	Non-hospitalized	Non-hospitalized	Non-hospitalized	Non-hospitalized	Non-hospitalized	Hospitalized	Non-hospitalized	Non-hospitalized	Non-hospitalized	Non-hospitalized
	Latency period from infection to medical evaluation (months)	10	14	16	4	10	10	13	14	11	9
Post-COVID	Main symptoms as prioritized by the patient	1. Dizziness 2. Tiredness 3. Pain	 Concentration problems Dizziness Thermostatic instability 	 Fatigue PEM Neurocognitive manifestations 	 Headaches Concentration problems Dizziness 	 Concentration problems Fatigue Headaches/ dizziness 	1. Brain fog 2. Headaches 3. PEM	 Pain Fatigue Neurocognitive manifestations 	1. Fatigue 2. Pain 3. Dizziness	1. Fatigue 2. Flu-like feeling 3. PEM	 Breathing problems Malaise with mild fever Fatigue/ tiredness
	OI/PoTS/OH	Ol	PoTS	OI	PoTS	OI	PoTS	PoTS	Ol	-	PoTS
	Bell Score ²	50-60	20	30	30	30	20-30	30	60	50	40-50
Ň	FSS ³	5.6	6.3	6.6	6.6	7.0	6.9	6.6	n. d.	6.0	6.8
PRC	CFQ ⁴	n. d.	n. d.	n. d.	n. d.	n. d.	n. d.	n. d.	11	n. d.	n. d.
	DSQ-PEM	+	+	+	+	+	+	+	+	+	+
MBSQs	000	+	-	+	+	+	+	+	+	+	+
	IOM	-	+	+	+	+	+	+	+	-	+
	PCD-J	-	-	+	+	n. d.	n.d.	n. d.	n. d.	n.d.	n. d.
	CDW-R	+	+	+	+	n. d.	n.d.	n.d.	n. d.	n.d.	n. d.
	PEM duration (hours)	> 24	> 24	> 24	> 24	> 24	> 24	> 24	> 24	> 24	> 24
M: male: F: female: RT-PCR: reverse transcription polymerase chain reaction: n d : not done: PEM: post-exertional malaise: MRT: magnetic resonance tomography: PET: pulmonary function testing: FEG: electroencephalography:											

M: male; **F**: female; **RT-PCR**: reverse transcription polymerase chain reaction; **n. d**.: not done; **PEM**: post-exertional malaise; **MRT**: magnetic resonance tomography; **PFT**: pulmonary function testing; **EEG**: electroencephalography; **PoTS**: postural orthostatic tachycardia syndrome; **OI**: orthostatic intolerance; **OH**: orthostatic hypotension; **PROMs**: patient-reported outcome measures; **FSS**: Fatigue Severity Scale, mean score); **CFQ**: Chalder Fatigue Scale, bimodal score; **DSQ-PEM**: DePaul Symptom Questionnaire-Post-Exertional Malaise; **MBSQs**: Munich Berlin Symptom Questionnaires; **CCC** = Canadian Consensus Criteria, **[46]**; **IOM**: Criteria of the former Institute of Medicine **[47]**; **PCD-J**: Pediatric Case Definition by Jason et al. **[48]**; **CDW-R**: Clinical Diagnostic Worksheet by Rowe et al. **[49]**; **hrs**: hours; ¹ anti-SARS-CoV-2 spike antibodies before vaccination and/or anti-SARS-CoV-2 nucleocapsid antibodies; ² Bell Score (%) (0% = entirely bedridden; 100% = normal daily functioning); ³ FSS (maximum value: 7); ⁴ CFQ (maximum value: 11)

777 FIGURES



778 Figure 1. Results from the Short Form 36 Health Survey (SF-36)

780 Spider diagrams display the different dimensions of the Short Form 36 Health Survey (SF-

36) for the ten MCFC patients with ME/CFS following COVID-19 (Post-COVID-ME/CFS),

the German norm population (age 14 - 20 years) from 1998 [70], and patients with

- moderate to severe depression (n = 60, mean age 17.5±1.6 years) [72].

- ----

798 Figure 2a. Frequency and Severity of Symptoms





811 812





of the Munich Berlin Symptom Questionnaires (MBSQs). Symptoms that are assessed differently in pediatric (n = 4) and adult patients (n = 6) are presented separately, as indicated. *New difficulties with math or other educational subject; **Marked weight

- 816 change and / or loss of appetite and / or abnormal appetite; ***New sensitivities to food,
- 817 *medication or chemicals.*